Research news // 6th April 2021
University College London launched a new smouldering myeloma study called COSMOS that aims to better understand why myeloma develops.
Only 50% of smouldering myeloma patients will develop myeloma. However, at the moment there is no good way to predict who will develop myeloma, and no effective treatment to prevent them from doing so.
This ground-breaking study aims to identify the changes in the immune function and plasma cell DNA that are associated with the progression smouldering myeloma to myeloma. The team at UCLH will measure the number and type of genetic changes in abnormal plasma cells responsible for smouldering myeloma and the number and function of the immune cells in blood and bone marrow.
It will help identify the patients who have the greatest risk of developing myeloma so they can be offered treatment or the chance to enrol in clinical trials. The information from the COSMOS study will also help researchers develop new treatments to prevent progression.
Recruitment to the study has started at University College London Hospitals with a plan to open further sites across the country.
The study lead Professor Kwee Yong, Consultant Haematologist at University College Hospitals, London said:
“We are excited to announce the opening of the COSMOS study that is now enrolling participants with smouldering myeloma. In COSMOS we want to understand how and why this condition develops into myeloma. If you have smouldering myeloma you may be able to take part. For more information contact the research team or visit the study website.”